Verona Pharma: Great Year For Share Price, But Competition Threatens Bull Thesis
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...
Fierce Biotech5d
Boehringer Ingelheim teams with Veeva to launch new R&D platform One Medicine
Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...